You are here

  • Home
  • Archive
  • Volume 23, Issue 8
  • Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era

Article Text

Article menu
Download PDFPDF
Cooperative Groups
Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting: Taking Endometrial Cancer Trials Into the Translational Era
  1. Carien L. Creutzberg, MD, PhD*,
  2. Henry C. Kitchener, MD†,
  3. Michael J. Birrer, MD, PhD‡,
  4. Fabio Landoni, MD§,
  5. Karen H. Lu, MD∥,
  6. Melanie Powell, MD,
  7. Carol Aghajanian, MD#,
  8. Richard Edmondson, MD**,
  9. Paul J. Goodfellow, PhD††,
  10. Michael Quinn, MD‡‡,
  11. Helga B. Salvesen, MD§§ and
  12. Gillian Thomas, MD∥∥
  1. *Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands;
  2. †Institute of Cancer Sciences, University of Manchester, United Kingdom;
  3. ‡Division of Hematology and Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA;
  4. §Division of Gynaecology, European Institute of Oncology, Milan, Italy;
  5. ∥Department of Gynecologic Oncology and Reproductive Medicine, MD Anderson Cancer Center, Houston, TX;
  6. Department of Clinical Oncology, Barts Health NHS Trust, London, United Kingdom;
  7. #Department of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY;
  8. **Department of Gynaecology, Newcastle University and Northern Institute for Cancer Research, Newcastle upon Tyne, United Kingdom;
  9. ††Department of Obstetrics and Gynecology, College of Medicine, Ohio State University, Columbus, OH;
  10. ‡‡Department of Gynaecologic Oncology, Royal Women’s Hospital, and Melbourne University Dept of Obstetrics and Gynaecology, Australia;
  11. §§Department of Obstetrics and Gynecology, Haukeland University Hospital; and Department of Clinical Medicine, University of Bergen, Norway; and
  12. ∥∥Department of Radiation Oncology, Sunnybrook Cancer Center, Toronto, Canada.
  1. Address correspondence and reprint requests to Carien L. Creutzberg, MD, PhD, Department of Clinical Oncology, Postzone K1-P, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: c.l.creutzberg@lumc.nl.

Abstract

Objective The second Gynecologic Cancer InterGroup (GCIG) Endometrial Cancer Clinical Trials Planning Meeting was held on December 1, 2012, and included international multidisciplinary representatives of the 24 member groups. The aims were to review recent advances in molecular pathology of endometrial cancer, focusing on molecular-based therapy, and to identify key hypotheses and issues to be addressed through international collaborative clinical trials.

Methods Reviews and summaries of current knowledge were presented followed by parallel working group sessions for surgery, adjuvant and systemic therapy, and translational research. Plenary discussions were held to integrate translational and clinical issues, and a final discussion session to agree on key trial concepts.

Results and Conclusions Proposals to take forward on the following trials were agreed: (1) lymphadenectomy to direct adjuvant treatment in women with high-risk endometrial cancer, including a sentinel node substudy; (2) conservative therapy for low-risk endometrial cancers in morbidly obese women with high surgical risks and for fertility-sparing treatment in premenopausal patients; (3) adjuvant therapy for women with early-stage carcinosarcoma. A proposal was made that a GCIG Early Phase Consortium be developed to serve as an international platform for rapid assessment of biomarkers.

  • Endometrial cancer
  • Randomised trials
  • Clinical trials planning meeting
  • International collaboration
  • Gynecological Cancer Intergroup

https://doi.org/10.1097/IGC.0b013e3182a26edb

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.

    • *Listed at the end of the manuscript.